Patents by Inventor Paul Kenneth Spearing

Paul Kenneth Spearing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
    Publication number: 20140323487
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction
    Patent number: 8822518
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 2, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
    Publication number: 20140100255
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu ZHANG, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Compounds as antagonists or inverse agonists at opioid receptors
    Patent number: 8633175
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: January 21, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Farnesoid X receptor agonists
    Patent number: 8158665
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: April 17, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X receptor agonists
    Patent number: 7960552
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: June 14, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Jonathan York Bass, III, Justin Caravella, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
    Publication number: 20110124559
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: August 8, 2007
    Publication date: May 26, 2011
    Applicant: Smithkline Beecham Corporation
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Farnesoid X Receptor Agonists
    Publication number: 20100249179
    Abstract: The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: June 13, 2008
    Publication date: September 30, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: David Norman Deaton, Frank Navas, III, Paul Kenneth Spearing
  • 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators
    Publication number: 20100240642
    Abstract: The present invention relates to certain indole derivatives that are modulators of PPAR?, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
    Type: Application
    Filed: August 31, 2007
    Publication date: September 23, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Jeffrey Alan Oplinger, Paul Kenneth Spearing, Millard Hurst Lambert, John A. Ray, Christopher P. Laudeman, Jerzy R. Szewczyk, Pierette Banker
  • NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
    Publication number: 20100222345
    Abstract: This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.
    Type: Application
    Filed: August 8, 2007
    Publication date: September 2, 2010
    Inventors: Caroline Jean Diaz, Curt Dale Haffner, Jason Daniel Speake, Cunyu Zhang, Wendy Yoon Mills, Paul Kenneth Spearing, David John Cowan, Gary Martin Green
  • Farnesoid X Receptor Agonists
    Publication number: 20100160398
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: March 9, 2010
    Publication date: June 24, 2010
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X Receptor Agonists
    Publication number: 20100120775
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: October 23, 2007
    Publication date: May 13, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Jonathan York Bass, III, David Norman Deaton, Justin Caravella, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X receptor agonists
    Patent number: 7705028
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: April 27, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blout McFayden, Frank Navas, III, Paul Kenneth Spearing
  • FARNESOID X RECEPTOR AGONISTS
    Publication number: 20080167356
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: December 13, 2006
    Publication date: July 10, 2008
    Applicant: SmithKline Beecham Corporation
    Inventors: Richard CALDWELL, David Norman Deaton, Robert Blount McFayden, Frank Navas, Paul Kenneth Spearing
  • Piperazinyltriazines as estrogen receptor modulators
    Patent number: 6943162
    Abstract: Triazine derivatives of formula (I), which exhibit pharmacological activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. The described invention also includes compositions and medicaments containing the triazine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: September 13, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Ronnie Lee Hale, Brad Richard Henke, Millard Hurst Lambert, III, Amy Tsai Lu, Paul Kenneth Spearing, Philip Stewart Turnbull
  • Piperazinyltriazines as estrogen receptor modulators
    Publication number: 20040072829
    Abstract: Triazine derivatives of formula (I), which exhibit pharmacological activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. The described invention also includes compositions and medicaments containing the triazine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.
    Type: Application
    Filed: July 21, 2003
    Publication date: April 15, 2004
    Inventors: Ronnie Lee Hale, Brad Richard Henke, Millard Hurst Lambert III, Amy Tsai Lu, Paul Kenneth Spearing, Philip Stewart Turnball